欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (5): 536-542.

• 定量药理学 • 上一篇    下一篇

H2受体拮抗剂应用与肺炎发生危险的Meta分析

胡爱虹1, 李小明1, 马欢杰2   

  1. 1浙江湖州市湖州第一人民医院药剂科,湖州 313000,浙江;
    2浙江省诸暨人民医院药剂科,诸暨311800,浙江
  • 收稿日期:2012-01-02 修回日期:2012-01-30 出版日期:2012-05-26 发布日期:2012-05-28
  • 作者简介:胡爱虹,女,主管药师,主要从事循证医学研究及临床药学工作。E-mail: hulixiaoming@sina.com

A Meta-analysis of histamine-receptor antagonists use and risk of pneumonia

HU Ai-hong1, LI Xiao-ming1, MA Huan-jie2   

  1. 1Department of Pharmacy,First People's Hospital of Huzhou, Zhejiang Province,Huzhou 313000 , Zhejiang ,China;
    2Department of Pharmacy,People's Hospital of Zhuji, Zhejiang Province, Zhuji 311800, Zhejiang ,China
  • Received:2012-01-02 Revised:2012-01-30 Online:2012-05-26 Published:2012-05-28

摘要: 目的:评估H2受体拮抗剂(histamine-receptor antagonists ,H2RA)应用是否增加肺炎的发生危险。方法: 应用计算机检索EMBASE 、CENTRAL(the Cochrane central register of controlledtrials)、Medline 、万方数据库、中国生物医学文献数据库系统(CBM)、中国期刊全文数据库(CNKI)等,搜集公开发表的关于H2RA应用与肺炎发生危险的随机对照研究(randomized controled trials, RCT)。以受试者肺炎发生的相对危险度(relative risk, RR)及相应的95%置信区间(95% confidence interval, 95%CI)作为效应指标进行合并统计量。各研究间的统计学异质性采用Q统计量的I2检验来分析,双侧P>0.05 认为各研究间不存在明显的统计学异质性,采用固定效应模型进行分析,反之采用随机效应模型进行分析。应用Egger法对发表偏倚进行量化检测。结果: 共有18篇研究符合纳入标准,2974例受试者,H2RA组1508例,对照组1466例。Meta分析显示,H2RA可增加受试者肺炎的发生风险(RR=1.22,95%CI=1.05~1.41,Z=2.61,P=0.009);亚组分析,H2RA与安慰剂相比,使受试者的肺炎风险增加21%(RR=1.21, 95%CI=1.02~1.45,Z=2.17,P=0.03),H2RA与硫糖铝相比并不增加受试者肺炎的发生风险(RR=1.22, 95%CI=0.93~1.60,Z=1.45,P=0.148)。结论:H2RA的应用可能是肺炎发生的一个危险因素。

关键词: 肺炎, H2受体拮抗剂, Meta分析

Abstract: AIM: To evaluate whether the use of histamine-receptor antagonists will increase the risk of pneumonia.METHODS: By searching EMBSE , CENTRAL(the Cochrane central register of controlledtrials), CBM, Medline, CNKI and WANFANG et al , we collected published randomized controled trials(RCTs) about histamine use and risk of pneumonia.The effect size was incidence of pneumonia measured relative risk (RR) and its 95% confidence interval (95%CI).The cochran's chi-square test (Q test) was used to test the statistical heterogeneity.The Egger test was used to test the publication bias.RESULTS:18 trials that included a total of 2974 subjects were included in the meta-analysi.1508 subjects were in the histamine-receptor antagonists group and 1466 were in the placebo of sucralfate group.The pooled relative risk of pneumonia was higher in histamine-receptor antagonists group compared with placebo/sucralfate group(RR=1.22,95%CI=1.05-1.41,Z=2.61,P=0.009). Sub-group analysis ,the pneumonia risk was increase 21% in histamine-receptor antagonists group compared with placebo group(RR=1.21, 95%CI=1.02-1.45,Z=2.17,P=0.03).But statistical difference was observed between histamine-receptor antagonists group and sucralfate group RR=1.22, 95%CI=0.93-1.60,Z=1.45, P=0.148).CONCLUSION: The use of histamine-receptor antagonists may increase the risk of pneumonia.

Key words: Pneumonia, Histamine-receptor antagonists, Meta-analyis

中图分类号: